The medical beauty market has steadily increased. In 20 19, the medical beauty market in China reached143.6 billion yuan, among which hyaluronic acid (sodium hyaluronate) medical beauty products were very popular. The share prices of Huaxi Bio and Aimeike, whose main business involves hyaluronic acid, have risen steadily, and Aimeike's performance has been driven by the positioning of "hi-body". As the only small molecular hyaluronic acid product of Class III equipment approved for cervical tattoo indications in China,
In 2008, Gaudemei modified hyaluronic acid gel for injection became the first approved hyaluronic acid for injection in China. Today, more than ten years later, the field of hyaluronic acid medical beauty has become a red sea. According to yost Sullivan's consulting report, in terms of sales volume, Gaudemei's market share of medical beauty hyaluronic acid products in 20 19 was about 9.5%, ranking second among foreign companies, but the relative unit price of foreign companies was higher. In terms of sales volume, Gaudemei's market share of medical beauty hyaluronic acid products in 20 19 years is about 14.5%.
Tong Yan Zhen is a mixture of poly-L-lactic acid and microspheres, which can stimulate the growth of collagen and achieve the purpose of firming skin. Poly (L- lactic acid) is an effective substance to stimulate skin to produce collagen, and microspheres are a slow-release means. At the same time, hyaluronic acid is added to play a physical role. There are some foreign "children's eyes" products on the market, such as Garneffei, Belle, Shu and so on. These products were not approved for listing in China, but flowed into China through informal channels.
Relatively speaking, hyaluronic acid injection is only a modified filling (it will return to its original state in a short time after absorption), and the effect of "Tong Yan Zhen" is much more lasting, so "Tong Yan Zhen" is also considered to be a heavy item in the field of medical beauty injection in the future. Sculptra, a product of Tong Yan Zhen, a subsidiary of Gaudemei, was approved by the US FDA as early as 2004, but it has not yet entered China. Lei Hongyu said that relevant clinical trials of Sculptra have been carried out in China, but it is not convenient to disclose the specific time of the trial and the specific time to market.
In terms of domestic enterprises, Aimeike's "childlike innocence" has completed on-site inspection. According to haitong international's speculation, the product was approved in June 20021year.